Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Lymphoid 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Ovarian Neoplasms 20Uterine Cervical Neoplasms 19Endometrial Neoplasms 9Stomach Neoplasms 8Melanoma 8Carcinoma, Renal Cell 8Squamous Cell Carcinoma of Head and Neck 7Colorectal Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Fallopian Tube Neoplasms 6Carcinoma, Hepatocellular 6Breast Neoplasms 6Pancreatic Neoplasms 5Carcinoma, Transitional Cell 5Triple Negative Breast Neoplasms 4Neoplasms 4Neoplasm Metastasis 4Head and Neck Neoplasms 4Esophageal Neoplasms 4Carcinoma, Merkel Cell 4Small Cell Lung Carcinoma 3Prostatic Neoplasms 3Sarcoma 2Recurrence 2Microsatellite Instability 2Lymphoma 2Kidney Neoplasms 2Carcinoma, Squamous Cell 2Carcinoma 2Vulvar Neoplasms 1

Interventions

pembrolizumab 3poly ICLC 1osimertinib 1durvalumab 1cobimetinib 1atezolizumab 1advexin 1Vorinostat 1Papanicolaou Test 1Nivolumab 1Human Papillomavirus DNA Tests 1High-Intensity Focused Ultrasound Ablation 1Colposcopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms, Squamous Cell × atezolizumab × Gynecologic × Clear all
NCT03544723 2020-06-09

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.

MultiVir, Inc.

Phase 2 Unknown
40 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicLymphoidThoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Hodgkin Disease, Liver Neoplasms, Lymphoma, Melanoma, Stomach Neoplasms, Carcinoma, Merkel Cell, Neoplasms, Squamous Cell, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡